Non-hyperglycemic obese and overweight patients who took any of three doses of canagliflozin lost more weight and attained modest BMI reductions compared with those in the placebo group, according to a study on the website of Obesity. However, researchers did not observe significant differences in baseline triglyceride or HDL cholesterol between the treatment groups.

Related Summaries